UK Community Advisory Board (UK-CAB)

UKCAB 45: HIV cure research


09:30 – 09:50 Registration, refreshments and expenses
09:50 – 10:00 Welcome, introductions, UKCAB updates
10:00 – 10:45 Conference feedback – Glasgow HIV11
Hepatitis guidelines update – Robert James
Pre-meeting for Dr Simon Barton
10:45 – 11.00 Break
11:00 – 12.00 Introduction to HIV cure research: pieces in the puzzle – Simon Collins, HIV i-Base
12:00 – 13:30 Lunch
13:30 – 14:30 Current research towards an HIV cure – Dr Sarah Fidler, Imperial College Hospital
14.30 – 16.00 HIV services in the new NHS – Dr Simon Barton, Chelsea and Westminster Hospital
16:00 – 16:15 AOB
16.15 Close

Presentations from this meeting – PDF files to download:
Introduction to HIV cure research: pieces in the puzzle
Current research towards an HIV cure
Meeting report

Background reading

The CHERUB collaboration
CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC) is a new approach to HIV therapeutics in the UK. CHERUB will be the first pan-BRC cooperative project to compete internationally in one of the most exciting new fields of biomedical research.

New approaches in HIV eradication research – 6 page download describing the major obstacles that need to be overcome and the key new advances and strategies designed to achieve an HIV cure. Although there is currently no cure for HIV infection, there has been a resurgence of interest in the field with the development of a number of potential new approaches, some of which have entered clinical trials.

Viral latency and eradication strategies – webcast: Professor Sharon Lewin, Alfred Hospital and Monash University, Melbourne, Australia speaking at the BHIVA Autumn conference

Towards a cure: early developments reported

Latest data on HIV cure research

The POZ website has a section on cure:
• What you need to know to keep the hope for the cure alive
• Cure research updates
• POZ TV webcasts from Timothy Brown, aka the Berlin patient, Dr Anthony Fauci, head of NIAID at the National Institutes of Health, and Kevin Frost from AmFAR.

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.